Solventum Corporation

- No specific mention of new fundraising through debt or equity in the current or future periods. - The company has been actively paying down debt, having paid down half of the original $8 billion debt since the spin. - Balance sheet strength is described as well positioned to execute a balanced capital plan, including share repurchases and tuck-in acquisitions. - They launched a $1 billion share repurchase program, signaling confidence in their cash flow and capital structure. - The company is focusing on tuck-in acquisitions funded from existing resources rather than raising new capital. - No explicit plans or announcements for new debt issuance or equity offerings were made on the call.

- Completed a strategic expansion of manufacturing facility in South Dakota to enhance supply chain flexibility for existing product growth and new product launches (Page 4). - Ongoing ERP cutovers and distribution center streamlining as part of separation from 3M, including multiple concurrent manufacturing and distribution center changes, closures, and openings (Pages 4, 8, 14). - Implementing a multiyear SKU rationalization program aimed at operational efficiency (Page 14). - Integration of Acera acquisition, a fast-growth acute care synthetic tissue business, supporting growth in Advanced Wound Care (Pages 2, 4, 14). - Launched a $1 billion multiyear share repurchase program leveraging strong balance sheet strength to balance capital return and tuck-in acquisitions (Page 14). - Transform for the Future program: a multiyear $500 million savings initiative focused on reshaping operating structure, increasing automation, optimizing global footprint, and repositioning spend toward high-return areas, with significant value expected from 2027 onward (Page 2).

- Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Page 14). - All segments forecasted to improve on an underlying basis, with commercial and innovation drivers propelling growth (Page 14). - Nearly 20 new product launches planned over the next 2 years, primarily new products focused on growth driver areas, supporting a steady cadence of launches and fueling commercial teams (Pages 2, 7, 10). - Volume is the main driver of growth, with price impacts remaining within ±1%, implying growth is primarily volume-based (Page 7). - Continued momentum in business and strengthening growth rates expected through 2026, despite tough comps and challenging macro environment (Pages 6, 13). - Specialized sales teams and innovation are enhancing commercial execution to drive growth across segments (Pages 2, 14). - ERP-related phasing of sales expected to impact quarterly timing but no change to full-year growth guidance (Pages 6, 13).

- Expectation of 2026 growth improvement over 2025, aligning with long-range plan (LRP) targets, driven by all segments improving with commercial and innovation enhancements (Wayde McMillan). - Q2 2026 anticipated to show improved EPS due to seasonally lower Q1 margins; additional $100 million sales expected, with ~30% drop-through to EPS (Wayde McMillan). - Full-year 2026 EPS expected toward the high end of the $6.40 to $6.60 range, reflecting strong execution and momentum (Page 5). - Operating margins forecasted to hold steady or improve, with Q1 strong margins slightly above 56% and subsequent quarters near but just under 56% (Wayde McMillan). - Transform for the Future program supports margin expansion through structural improvements and cost savings, with significant benefits targeted for 2027 and beyond. - Portfolio optimization and innovation pipeline (20 new products over 2 years) expected to fuel growth and profit expansion.

- There is an estimated over $100 million of advanced orders expected in Q2 due to the upcoming ERP cutover in the U.S. and Canada, primarily impacting IPSS and Dental segments. - These advanced orders in Q2 are part of a mitigation strategy to ease order and shipment volumes during the Q3 ERP cutover. - The advanced orders in Q2 will be offset by reduced orders in the second half of 2026, mostly in Q3, effectively resulting in sales timing rather than incremental sales. - Overall, the impact on the full-year guidance is neutral, with no changes expected due to this order phasing. - Sales phasing details and exact order shipments will be updated with the Q2 report. - The company has high confidence in managing this orderbook through distribution channels, especially in the U.S., to ensure product availability during system transitions.